Italy Patent System

Italy is the second-largest pharmaceutical manufacturer in Europe (after Germany). Major Italian pharma companies include Menarini Group (Florence — cardiovascular, antidiabetic, antibiotics), Recordati (Milan — rare diseases, cardiology), Angelini Pharma (Rome — CNS, pain), Chiesi Farmaceutici (Parma — respiratory), and Bracco (Milan — diagnostic imaging contrast agents). Italy also hosts large manufacturing operations for global pharma companies (Novartis, Pfizer, Roche manufacturing sites). Italian pharmaceutical patents include both UIBM national patents and EP patents validated in Italy. Italy has supplementary protection certificates (SPCs) under EU SPC Regulation 469/2009 — directly applicable, requiring no Italian implementation. AIFA (Agenzia Italiana del Farmaco — Italian drug regulator) authorization date determines Italian SPC term alongside EMA authorization. Italy implemented pharmaceutical patent linkage in connection with EU rules, creating interactions between AIFA marketing approvals and patent status for generic drug registrations.

Italy's automotive industry — centered in Emilia-Romagna ('Motor Valley': Ferrari, Lamborghini, Maserati, Ducati, Pagani) and Turin (Fiat/Stellantis, Pininfarina) — generates significant patent activity in both technical (powertrain, chassis, electronics, EVs) and design categories. Ferrari (S.p.A., Maranello) holds thousands of patents covering engine technology, aerodynamics, electronics, and trademark-adjacent technical features. Ferrari's design patents (registered with EUIPO as Registered Community Designs and at UIBM) protect the distinctive vehicle silhouettes and body elements. Pininfarina (now a subsidiary of Mahindra) is one of the world's most prolific automotive design studios — holding design IP on iconic cars including the Ferrari 308, Ferrari Testarossa, Cadillac Allanté, and Alfa Romeo Spider. Italy's luxury goods sector (Gucci, Prada, Armani, Versace — all with significant fashion patent and design portfolios) adds to Italy's position as Europe's leading design-patent jurisdiction by number of filings in fashion and luxury goods categories.

For most international applicants, a European Patent (EP) validated in Italy — or a Unitary Patent covering Italy and 16+ other EU states — is the better choice compared to a direct Italian national patent at UIBM. The reasons are: (1) EPO examination quality and recognition: the EPO is recognized globally for rigorous patent examination. An EPO-granted patent carries more commercial weight than a UIBM-granted national patent. Large Italian companies, pharmaceutical firms, and multinationals rely on EP-validated patents for their Italian market protection; (2) Unitary Patent efficiency: since June 1, 2023, Italy is a UPC participating state. Applicants can now request Unitary Patent status after EPO grant — one registration covering Italy, Germany, France, the Netherlands, Spain, and 15+ other EU states. This eliminates the need for separate national validation fees in each country; (3) Italian translation: Italian national EP validation requires translation into Italian (Italy has not adopted the London Agreement on translation requirements, unlike Germany, France, and the UK). This adds cost relative to some other EPC states; (4) UIBM national patent use cases: UIBM national patents are primarily used by Italian SMEs, artisanal manufacturers, and individual inventors who want domestic protection at lower cost than EP prosecution. The Italian utility model (Modello di Utilità) — which requires only novelty + creative character, not full inventive step — is also a useful and cost-effective protection tool at UIBM for mechanical and product innovations.

The UPC Local Division Milan is one of the first-instance courts of the Unified Patent Court (UPC), which entered into force on June 1, 2023. It hears: (1) Infringement actions: claims that a Unitary Patent or a non-opted-out EP patent is being infringed in Italy. The plaintiff files in the UPC Local Division Milan if the infringement occurred in Italy or if the defendant is established in Italy. A UPC judgment from Milan is enforceable across all UPC participating states — Italian proceedings can produce EU-wide injunctions; (2) Counterclaims for revocation: when a defendant in an infringement action at the Milan Local Division seeks to invalidate the patent, they can file a counterclaim for revocation directly in Milan. Milan can hear both the infringement claim and the invalidity counterclaim — no bifurcation between infringement and validity; (3) Declarations of non-infringement: available at the Central Division in some cases. Italy's choice of Milan (not Rome) reflects Italy's commercial legal tradition — Milan is Italy's business and financial capital, with the largest IP law firms, the Court of Milan's pre-existing Sezione Specializzata (specialized IP court section), and proximity to Italy's northern industrial cluster (Emilia-Romagna, Lombardy, Veneto — automotive, machinery, pharmaceuticals). The Milan Local Division proceedings are primarily in Italian, with the option to request proceedings in English for all parties. For patent holders with Unitary Patents or EP patents covering Italy, the UPC Local Division Milan enables EU-wide enforcement from a single Italian proceeding — a significant upgrade from the old system requiring separate national proceedings in each EU country.

Italian law (Article 64 of the Codice della Proprietà Industriale — CPI) classifies employee inventions into three categories with different ownership and compensation rules: (1) Service inventions (invenzioni di servizio): inventions made in the performance of an employment relationship that specifically contemplates inventive activity as the employee's primary role — where the invention is the expected output of the employment. These belong automatically to the employer. No additional compensation beyond the employment salary is required; (2) Corporate inventions (invenzioni aziendali): inventions made in the performance of employment activities where the employment involves inventive activity among other roles — but inventing is not the sole or primary expectation. These also belong to the employer, but the employee is entitled to equo premio (fair prize/compensation). The amount is determined based on: the commercial value of the invention, the degree of use of the employer's means and resources, and the contribution of the employer's knowledge and information. If parties cannot agree, the amount can be determined by the Commissione delle Invenzioni (Invention Commission) or a court; (3) Occasional inventions (invenzioni occasionali): inventions made by an employee in a field covered by the employer's business activity but outside the employee's employment duties. The employer has a right of pre-emption — the right to acquire or exploit the invention, but must pay equo compenso (fair compensation) within 3 months of disclosure. If the employer does not exercise this right within 3 months, the employee retains full ownership. For US companies with Italian employees: the automatic ownership of service and corporate inventions by Italian employers (without requiring a separate IP assignment agreement) differs from US law (where employees own inventions unless they sign a PIIA). The mandatory equo premio for corporate inventions is a statutory right that cannot be contractually waived — employment agreements attempting to eliminate this right are unenforceable.

An Italian utility model (Modello di Utilità) under Article 82 of the Codice della Proprietà Industriale provides 10 years of protection for devices, objects, or products that exhibit a particular efficacy or utility derived from their configuration, structure, or combination of parts. Key characteristics: (1) Lower threshold than invention patents: Italian utility models require novelty and industrial applicability, plus 'creative character' (carattere creativo) — a lower bar than the full inventive step required for invention patents. A modest structural improvement that provides practical benefit can qualify as a utility model even if it would fail the non-obviousness standard for a patent; (2) Objects and products only — NOT processes: utility models cover the configuration or structure of physical objects. You cannot protect a method, process, or chemical substance as an Italian utility model; (3) UIBM examination: Italian utility models are examined (unlike some countries with registered-only, unexamined utility models), but the examination is lighter than for invention patents; (4) 10-year term: compared to 20 years for an invention patent. Trade-off: if your product life cycle is under 10 years, the utility model term is adequate; (5) Cannot have both: you cannot simultaneously hold an Italian utility model and an Italian invention patent on the same innovation; When to use Italian utility models: (a) Incremental improvements to mechanical products, medical devices, industrial equipment, or precision instruments — Italy's manufacturing tradition (Made in Italy mechanical engineering) is well-suited; (b) Fashion accessories with functional elements — Italy's fashion industry includes products where both design registration and utility model protection apply to different aspects; (c) When speed and cost matter: UIBM utility model examination is typically faster than full invention patent examination.

Italy's pharmaceutical patent system operates at both the European level (through the European Patent Convention and EU regulations) and the national level (through UIBM and AIFA — the Italian drug regulator). Key elements: (1) Supplementary Protection Certificates (SPCs): Italy applies the EU SPC Regulation (Regulation 469/2009) directly — no separate Italian SPC law is needed, as EU regulations are directly binding on EU member states. The Italian SPC extends a patent covering a pharmaceutical or plant protection product by the time lost during regulatory approval, minus 5 years. Maximum SPC extension: 5 years. The Italian SPC term is calculated using the AIFA (Agenzia Italiana del Farmaco) marketing authorization date — typically the same as the EMA marketing authorization date, but not always (Italy sometimes issues parallel national authorization before or after EMA). The SPC must be filed at UIBM within 6 months of the first Italian/EU marketing authorization; (2) Pediatric extension: Italian SPCs can receive a 6-month pediatric extension (complying with the Paediatric Regulation EC 1901/2006), consistent with other EU member states; (3) Bolar exemption: Italy implements the EU Bolar exemption (Directive 2004/27/EC) — allowing generic manufacturers to use patented drugs for regulatory submission purposes without infringing the patent, preparing market entry for the day the patent/SPC expires; (4) Generic drug linkage: Italy's AIFA requires generic drug applicants to certify patent status (the Italian 'patent linkage' system is weaker than the US Hatch-Waxman Orange Book system but requires AIFA awareness of relevant patents); (5) Italian pharma sector scale: Italy is Europe's second-largest pharmaceutical manufacturer, with significant R&D and manufacturing capacity from Menarini, Recordati, Angelini, Chiesi, and Bracco, as well as major operations from global companies (Novartis, Pfizer, Roche). Italian pharma patent disputes frequently involve originator vs. generic company proceedings at specialized IP courts (Sezioni Specializzate in Materia di Impresa) in Milan, Rome, and Turin.